BR112013004401A2 - metodo para produzir uma partícula lipídica, as partículas lipídicas propriamente ditas e seu uso. - Google Patents

metodo para produzir uma partícula lipídica, as partículas lipídicas propriamente ditas e seu uso.

Info

Publication number
BR112013004401A2
BR112013004401A2 BR112013004401A BR112013004401A BR112013004401A2 BR 112013004401 A2 BR112013004401 A2 BR 112013004401A2 BR 112013004401 A BR112013004401 A BR 112013004401A BR 112013004401 A BR112013004401 A BR 112013004401A BR 112013004401 A2 BR112013004401 A2 BR 112013004401A2
Authority
BR
Brazil
Prior art keywords
lipid
producing
particles themselves
lipid particle
solution
Prior art date
Application number
BR112013004401A
Other languages
English (en)
Inventor
Anton Jochner
Hubert Kettenberger
Martin Bader
Monika Baehner
Silke Mohl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013004401A2 publication Critical patent/BR112013004401A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

metodo para produzir uma partícula lipídica, as partículas lipídicas propriamente ditas e seu uso. expóe-se neste contexto um método para produzir uma partícula lipídica que compreende as seguintes etapas: i) proporcionar uma primeira solução que compreende apolipoproteína desnaturada, ii) adicionar a primeira solução e uma segunda solução que compreende pelo menos dois lipídeos e um detergente, mas nenhuma apolipoproteína, e iii) remover o detergente partir da solução obtida na etapa ii) e produzir dessa forma uma partícula lipídica.
BR112013004401A 2010-08-30 2011-08-25 metodo para produzir uma partícula lipídica, as partículas lipídicas propriamente ditas e seu uso. BR112013004401A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10008994 2010-08-30
PCT/EP2011/064601 WO2012028525A2 (en) 2010-08-30 2011-08-25 Method for producing a lipid particle, the lipid particle itself and its use

Publications (1)

Publication Number Publication Date
BR112013004401A2 true BR112013004401A2 (pt) 2016-05-17

Family

ID=44509389

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013004401A BR112013004401A2 (pt) 2010-08-30 2011-08-25 metodo para produzir uma partícula lipídica, as partículas lipídicas propriamente ditas e seu uso.

Country Status (9)

Country Link
EP (1) EP2611417A2 (pt)
JP (1) JP2013538205A (pt)
KR (1) KR20130117760A (pt)
CN (1) CN103068369A (pt)
BR (1) BR112013004401A2 (pt)
CA (1) CA2807441A1 (pt)
MX (1) MX2013001539A (pt)
RU (1) RU2013111676A (pt)
WO (1) WO2012028525A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838814A1 (en) 2011-08-25 2013-02-28 F.Hoffmann-La Roche Ag Cation and anion exchange chromatography method
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608347A (en) * 1982-04-15 1986-08-26 Bernstam Victor A Compositions, uses and methods creating reverse micelles for the clarification of biological fluids to obtain undistorted assay of analytes following clarification
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
EP0972838B1 (en) 1998-07-15 2004-09-15 Roche Diagnostics GmbH Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy
US6291245B1 (en) 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
AU2001253620A1 (en) 2000-04-14 2001-10-30 Nuvelo, Inc. Materials and methods relating to lipid metabolism
JP4344136B2 (ja) * 2000-11-10 2009-10-14 エフ・ホフマン−ラ・ロシュ・リミテッド アポリポタンパク質類似体
EP1382614A1 (en) * 2002-07-15 2004-01-21 Bayer HealthCare AG Process for the purification of interleukin-4 and its muteins
CA2443365C (en) 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
US20040180445A1 (en) * 2003-03-12 2004-09-16 Domanico Michael J. Methods and compositions for purification of nucleic acid from a host cell
ES2253604T3 (es) 2003-06-12 2006-06-01 F. Hoffmann-La Roche Ag Metodo para la produccion recombinante de polipeptidos.
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
US7608278B2 (en) * 2003-12-30 2009-10-27 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
US20060019870A1 (en) 2004-01-28 2006-01-26 O'donnell Francis E Jr Apoprotein cochleate compositions
JP2008514240A (ja) * 2004-10-01 2008-05-08 インヴィトロジェン コーポレーション 生体分子のインビトロ合成用の供給バッファー、系、及び方法
US20060214104A1 (en) * 2004-10-26 2006-09-28 Invitrogen Corporation Compositions and methods for analyzing biomolecules using mass spectroscopy
WO2006069371A1 (en) * 2004-12-22 2006-06-29 Baylor College Of Medicine A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
WO2006125304A1 (en) 2005-05-25 2006-11-30 Liponex, Inc. Pharmaceutical compositions for treating or preventing coronary artery disease
EP2537526A1 (en) 2006-06-01 2012-12-26 Institut de Cardiologie de Montréal Method and compound for the treatment of valvular stenosis
US20080064071A1 (en) * 2006-07-25 2008-03-13 Hogrefe Holly H Zwitterionic detergents for the storage and use of DNA polymerases
FR2915490B1 (fr) * 2007-04-26 2011-10-28 Univ Joseph Fourier Grenoble I Formation de proteoliposomes contenant des proteines membranaires a l'aide d'un systeme de synthese proteique acellulaire
JP2010539995A (ja) * 2007-10-08 2010-12-24 アナフォア インコーポレイテッド 三量体ＩＬ−１Ｒａ
US8999320B2 (en) * 2008-01-30 2015-04-07 The Rockefeller University Nanoscale bound bilayers, methods of use and production
CA3013503A1 (en) 2008-04-25 2009-10-29 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules

Also Published As

Publication number Publication date
CA2807441A1 (en) 2012-03-08
MX2013001539A (es) 2013-03-18
WO2012028525A3 (en) 2012-10-26
CN103068369A (zh) 2013-04-24
RU2013111676A (ru) 2014-10-10
JP2013538205A (ja) 2013-10-10
WO2012028525A2 (en) 2012-03-08
EP2611417A2 (en) 2013-07-10
KR20130117760A (ko) 2013-10-28

Similar Documents

Publication Publication Date Title
AR098890A1 (es) Proceso para obtener aceite microbiano a partir de células microbianas
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
BR112014012221A2 (pt) método para produção de uma escova de dentes que tem uma cavidade interna
BR112014013175A8 (pt) composições de liberação prolongada baseadas em lipídios anfipáticos e processo para preparar comprimidos de composição de liberação prolongada
EA201391602A1 (ru) Контролируемое высвобождение иммунодепрессантов из синтетических наноносителей
BR112015029835A2 (pt) aparelho, e, método de formação de uma estrutura consolidada
CR20130676A (es) Composiciones de lipidos algales y metodos para prepararlas y utilizarlas
BR112015029254A2 (pt) composição detergente de baixo ph compreendendo tensoativos não iônicos
BR112013004397A2 (pt) método para produzir uma partícula de lipídio, a partícula de lipídio em si e seu uso
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
AR091228A1 (es) Metodo para producir un organismo mejorado vegetal infectado establemente con un endofito
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
BR112015006402A2 (pt) conjunto de pelo menos uma proteína vegetal e pelo menos uma proteína láctea
CL2011000797A1 (es) Metodo para producir anticuerpos a partir de celulas plasmaticas que comprende el cultivo de celulas plasmaticas en cantidades limitadas.
CY1121304T1 (el) Μεθοδος καθαρισμου σαπωνινων
BR112015000582A2 (pt) método, e composição
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
CO6731125A2 (es) Proceso para la preparación de 4-amino-3-cloro-5-fluoro-6-picolinatos (sustituidos)
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
AR086586A1 (es) Forma cristalina de ciclosporina a, metodos de preparacion y metodos para utilizar la misma
BR112012029919B8 (pt) Processo para preparação de 8-alcóxi [1,2,4] triazolo[1,5-c]pirimidin-2-aminas, substituídas na posição 5, e seus intermediários
CL2015002837A1 (es) Compuestos de piridinilpirazoloquinolina.
TN2013000373A1 (en) Pharmaceutical formulation comprising inositol
ECSP13013094A (es) Composiciones de limpieza de sal colina

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]